Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod in moderately to severely active Crohn's disease
NCT03464097Phase 3Terminated
- Sponsor
- Celgene Corporation
- Start
- Jun 2018
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 49
01
Overview
A Phase 3 trial of ozanimod in Crohn's disease, sponsored by Celgene Corporation. Started Jun 2018; status: terminated.
02
Drugs
ozanimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03464097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03464097.